- Home
- BNR vs ESLA Comparison
BNR vs ESLA Comparison
Compare BNR & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- ESLA
- Stock Information
- Founded
- BNR 2014
- ESLA 2021
- Country
- BNR China
- ESLA United States
- Employees
- BNR N/A
- ESLA N/A
- Industry
- BNR Medical Specialities
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BNR Health Care
- ESLA Health Care
- Exchange
- BNR Nasdaq
- ESLA Nasdaq
- Market Cap
- BNR 38.3M
- ESLA 35.5M
- IPO Year
- BNR 2020
- ESLA N/A
- Fundamental
- Price
- BNR $4.68
- ESLA $0.85
- Analyst Decision
- BNR
- ESLA Strong Buy
- Analyst Count
- BNR 0
- ESLA 1
- Target Price
- BNR N/A
- ESLA $16.00
- AVG Volume (30 Days)
- BNR 17.3K
- ESLA 15.8K
- Earning Date
- BNR 08-21-2025
- ESLA 08-20-2025
- Dividend Yield
- BNR N/A
- ESLA N/A
- EPS Growth
- BNR N/A
- ESLA N/A
- EPS
- BNR N/A
- ESLA N/A
- Revenue
- BNR $72,112,038.00
- ESLA N/A
- Revenue This Year
- BNR $136.32
- ESLA $101.09
- Revenue Next Year
- BNR N/A
- ESLA N/A
- P/E Ratio
- BNR N/A
- ESLA N/A
- Revenue Growth
- BNR 0.53
- ESLA N/A
- 52 Week Low
- BNR $2.18
- ESLA $0.63
- 52 Week High
- BNR $7.90
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- BNR 69.57
- ESLA 41.00
- Support Level
- BNR $4.47
- ESLA $0.82
- Resistance Level
- BNR $4.96
- ESLA $0.88
- Average True Range (ATR)
- BNR 0.25
- ESLA 0.08
- MACD
- BNR 0.11
- ESLA -0.00
- Stochastic Oscillator
- BNR 84.31
- ESLA 27.78
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.